Recent real-world data from the STEER study showed that Wegovy (semaglutide) led to a 57% greater reduction in major adverse cardiovascular events (heart attack, stroke, or death) compared to the rival drug Tirzepatide in adults with obesity and cardiovascular disease (but no diabetes). HCPLive+1 This finding is especially interesting for college-age users because drug-trends (especially weight-loss drugs) often get huge hype on social media, and statements like “this drug prevents heart attacks” can spread fast without full context.
However, the claim needs nuance: the population studied had pre-existing cardiovascular disease and obesity; it’s not a universal "everyone who takes Wegovy will massively reduce their heart-attack risk" scenario. Also, it was a retrospective observational study, not a randomized controlled trial, so cause-and-effect is less certain. Reuters Because this claim involves a popular wellness/fitness drug, big promises about it, and potential for misunderstanding among young adults, it’s a key candidate for fact-checking.
